Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study

Dong-Yun Kim; In Gyu Hwang; Sun Mi Kim; Dae Ryong Kang; Tae-Hwa Go; Se Hwa Hong; Shin Young Park; Hyunho Lee; Jin Hwa Choi

doi:10.4143/crt.2024.554

Articles

Page Path: HOME > Cancer Res Treat > Volume 57(4); 2025 > Article

Original Article Lung and Thoracic cancer Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study: Dong-Yun Kim^1,2, In Gyu Hwang³, Sun Mi Kim⁴, Dae Ryong Kang^5,6, Tae-Hwa Go⁵, Se Hwa Hong⁵, Shin Young Park⁷, Hyunho Lee⁷, Jin Hwa Choi^1,2; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2025;57(4):1030-1039.
DOI: https://doi.org/10.4143/crt.2024.554
Published online: February 6, 2025

¹Department of Radiation Oncology, Chung-Ang University Hospital, Seoul, Korea

²Department of Radiation Oncology, Chung-Ang University College of Medicine, Seoul, Korea

³Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea

⁴Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea

⁵Department of Medical Informatics and Biostatistics, Yonsei University Wonju College of Medicine, Wonju, Korea

⁶Department of Precision Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea

⁷Anticancer Strategy Research Institute, VSPharmTech Co., Ltd., Seoul, Korea

Correspondence: Jin Hwa Choi, Department of Radiation Oncology, Chung-Ang University College of Medicine, 84 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: 82-2-6299-2676 E-mail: bonnybee@cau.ac.kr

• Received: June 12, 2024 • Accepted: February 5, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

2,330 Views
104 Download
1 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Antipsychotic drugs (APDs) can be used to relieve psychological symptoms in patients with cancer. We investigated the nationwide use of APDs during concurrent chemoradiotherapy (CCRT) for patients with lung cancer and its association with overall survival (OS).
Materials and Methods
The National Health Service database was used in this retrospective cohort study. Patients diagnosed with lung cancer between 2010 and 2020 who received cisplatin-based CCRT were included. The APDs included in the analysis were aripiprazole, quetiapine, olanzapine, risperidone, haloperidol, and chlorpromazine, and the APD prescription details included prescription time, dosage, and duration.
Results
Among the 23,099 patients with lung cancer treated with CCRT, 2,662 (11.5%) took APDs concurrently. Quetiapine (47.3%) and chlorpromazine (36.6%) were the frequently prescribed APDs. In the univariate analysis, patients prescribed APDs during CCRT had a significantly worse OS than those who did not take APDs. The 2-year OS rates for APD (+) and APD (–) patients were 20.4% and 36.4%, respectively (p < 0.001). Multivariable analyses revealed that APD prescription, male, age > 80 years, and comorbidities, such as hypertension, myocardial infarction, and depressive disorder, significantly influenced OS. In patients who used APDs during CCRT, APD prescription timing (pre-CCRT vs. during CCRT), dosage (low vs. high) and duration (within 6 months vs. over 6 months) had no significant difference.
Conclusion
Overall, 11.5% of patients with lung cancer used APDs during CCRT. Patients who used APDs during CCRT had poorer survival than those who did not. Further studies are required to elucidate the effects of APDs on patients with cancer.
Key words: Lung neoplasms, Antipsychotic agents, Chemoradiotherapy

Introduction

Globally, lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths [1,2]. Global cancer statistics for 2020 reported approximately 2.2 million newly diagnosed patients with lung cancer and 1.8 million cancer deaths worldwide [3]. Lung cancer is considered incurable in advanced cases, and the cure rate is only 15%-30% with the standard treatment of cisplatin-based concurrent chemoradiotherapy (CCRT) [4]. In Korea, lung cancer incidence has been increasing steadily since 1999, doubling in the last 20 years [5]. In particular, lung cancer in Korea is prevalent in older patients, who may be more vulnerable to mental health issues due to a higher prevalence of comorbidities compared to younger patients [6].

People with cancer are increasingly experiencing a wide range of psychiatric disorders. The most prevalent conditions include delirium, depression, adjustment disorders, anxiety, sexual dysfunction, and sleep disturbances, affecting 30%-40% of patients with cancer. These issues are particularly common in individuals with advanced-stage cancer [7,8]. Antipsychotic drugs (APDs) can attenuate the subjective symptoms of delirium, agitation, or other mood disorders often accompanying cancer treatment [9,10]. In the context of psycho-oncology, APDs are frequently used to manage various symptoms beyond those typically treated in general psychiatric settings. While their primary use is to manage delirium, confusion, agitation, and manic episodes, they also play a valuable role in mitigating anxiety, insomnia, nausea, and stimulating appetite [11,12]. Furthermore, APDs are frequently used off-label to manage drug-induced psychotic symptoms and alleviate pain in various oncology contexts [13]. In the treatment of lung cancer, challenging multimodality treatments, such as CCRT, can cause or worsen psychiatric symptoms such as delirium. In particular, older patients who are commonly affected by lung cancer may have higher risk of developing treatment-related psychiatric disorders [14]. Moreover, older patients are commonly on medications for their pre-existing conditions alongside cancer treatment. Consequently, when psychiatric disorders develop or symptoms arise that necessitate the use of medication, careful consideration should be given to the administration of APDs. Thus, further research is needed on the use of APDs and an assessment of their current applications. However, to date, no studies have addressed this issue in patients with lung cancer.

Therefore, we aimed to investigate the use of APDs in patients with lung cancer receiving CCRT in a real-world setting. We also explored the survival data from a nationwide healthcare database managed by the National Health Insurance Service (NHIS) in Korea.

Materials and Methods

1. Databases and study population

This study used data from NHIS database between 2010 and 2020. NHIS provided medical claims data for the entire population in Korea. Diagnosis codes in NHIS use the Korean Standard Classification of Diseases. We first screened for patients with diagnosis codes C00-C97 during the period. From the total patients with cancer, we selected eligible patients who were diagnosed with lung cancer and received CCRT. In the dataset, chemotherapy drugs were limited to cisplatin, which is mainly used as a CCRT regimen in advanced-stage lung cancer. CCRT cases were defined by those where chemotherapy was claimed during the period when radiotherapy (RT) was also claimed. Among the patients with lung cancer who received CCRT, we screened the patients who had been prescribed APDs, including aripiprazole, quetiapine, olanzapine, risperidone, haloperidol, and chlorpromazine. The claim data included age, sex, Charlson Comorbidity Index (CCI), and comorbidities, including cardiovascular disease and psychiatric disorders. Excluding cancer, the diagnosis codes included in the analysis were hypertension (I10-I15), myocardial infarction (I21, I22), bipolar disorder (F30, F31), psychotic disorder (F20-F29), depressive disorder (F32-F34), delirium (F05), and other psychiatric disorders (F00-F99). The history of hypertension, myocardial infarction, and psychiatric history (bipolar disorder, psychotic disorder, depressive disorder, delirium, and other psychiatric disorders) included all diagnoses made throughout the study period. The psychiatric history presented in Table 1 includes only psychiatric disorders diagnosed prior to the initiation of CCRT for lung cancer.

Although the diagnosis code for lung cancer included non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), NHIS data did not include information on the stage. However, we could estimate the approximate stage of the patients with lung cancer who received CCRT. In NSCLC, CCRT is administered in stage IIIA and above, or in IIB, when the cancer is inoperable N1. In SCLC, CCRT is administered in limited stage diseases from IIB to IIIC. Therefore, the patients with lung cancer included in the analyses were generally in locally advanced stages.

2. Prescriptions for APDs

Patients with a CCRT claim were considered to have been prescribed an APD if they had at least one APD claim. Patients who were prescribed APD before starting CCRT, with the duration of APD administration overlapping with that of CCRT, as well as those who were prescribed APD during CCRT, were included in the APD groups. Based on the CCRT and APD prescription dates, patients who were prescribed APD before starting CCRT were included in the pre-CCRT group and those who were prescribed APD during CCRT were included in the during-CCRT group.

APD prescriptions were categorized as “simple prescription,” where only one drug was prescribed, and “complex prescription,” where two or more drugs were prescribed simultaneously. The prescription dosage of APD was classified as low or high based on the prescribed dose on a simple prescription basis. Equivalent doses were determined based on chlorpromazine, where 100 mg/day of chlorpromazine is equivalent to quetiapine 60 mg/day, olanzapine 3 mg/day, risperidone 0.8 mg/day, aripiprazole 4 mg/day, and haloperidol 1.6 mg/day. We adopted the concept of high dose from Leucht et al. [15] as follows: chlorpromazine 250 mg/day, quetiapine 150 mg/day, olanzapine 7.5 mg/day, risperidone 2 mg/day, aripiprazole 10 mg/day, and haloperidol 4 mg/day.

3. Statistical analysis

The chi-squared test or independent Student t test were used for comparing the differences in categorical or continuous variables. For all analyses, categorical variables are expressed as frequencies and percentages, whereas continuous variables are expressed as mean±standard deviation. Using the Cox proportional hazards regression analysis, we estimated the risk of mortality with hazard ratios (HRs) and 95% confidence intervals (CIs). We conducted a survival analysis of the prognostic factors that potentially affected overall survival (OS). The starting date of the survival analysis was defined as day 1 of CCRT in patients and the endpoint was defined as the date of the patient’s death or December 31, 2020, for patients who survived. Attrition occurred when patients were no longer available for follow-up due to death, emigration, or loss of National Health Insurance eligibility; thus, data up to the last observation point were included in the analysis. The analysis included APD use, age, hypertension, myocardial infarction, psychiatric history (bipolar disorder, psychotic disorder, depression, delirium, and other psychotic disorders), and CCI. We used univariate analysis to identify the impact of each variable on survival. Subsequently, multivariable analysis was applied to determine the associations between multiple variables and survival, thereby identifying significant factors. All data were analyzed using SAS ver. 9.4 (SAS Institute, Inc.) and R ver. 4.1.3 (R Foundation for Statistical Computing), with a significance level of alpha=0.05.

Results

1. Baseline characteristics of patients and details of prescribed APD

According to the NHIS dataset, of the 977,706 patients with cancer, 23,099 received CCRT after being diagnosed with lung cancer. Among them, 2,662 (11.5%) received APDs during CCRT (Fig. 1).

Among the patients who took APDs during CCRT, 2,375 (89.2%) were male. The age distribution of patients who took APDs during CCRT was as follows: 0.7%, 4.3%, 20.4%, 40.2%, 30.8%, and 3.5% of patients in their 30s, 40s, 50s, 60s, 70s, and 80s, respectively. Among the patients with three or more CCIs, 58.9% took APDs and 56.6% did not. The patients who took APDs had the following underlying medical conditions: 1,619 patients (60.8%) had hypertension (I10-I15) and 174 (6.5%) had a previous myocardial infarction (I21, I22). Additionally, 64.9% of patients using APDs during CCRT had a psychiatric history, compared with 50.9% of patients who did not use APDs during CCRT. The underlying psychiatric conditions included bipolar disorder (F30, F31), psychotic disorder (F20-F29), depressive disorder (F32-F34), delirium (F05), and other psychiatric disorders (F00-F99) in 10.3%, 4.4%, 30.1%, 2.1%, and 30.2% patients, respectively. Compared with the patients who did not use APDs during CCRT, those who took APDs had higher rates of most comorbidities (Table 1).

Information on the types of the prescribed APDs is described in Table 2. For simple prescriptions, the most commonly prescribed APD during CCRT were quetiapine (47.6%), chlorpromazine (39.1%), olanzapine (8.2%), and risperidone (5.2%). The proportion of patients who received complex prescriptions of APDs during CCRT was 5.3% (141 of 2,662 patients). Patients prescribed two APDs accounted for 97.2% of the total, whereas those prescribed three or more APDs accounted for 2.8%. Meanwhile, details of the timing, dosage (low vs. high), and duration of the prescribed APDs during CCRT are shown in Table 2. Of the patients who took APDs during CCRT, 20% and 80% were in the pre-CCRT and during-CCRT groups, respectively. Regarding prescribed dosages, 96.3% of patients received a low dosage, whereas 3.7% received a high dosage. A majority were prescribed for less than 6 months (91.7%), whereas 8.3% of patients were prescribed for more than 6 months during and after CCRT.

2. Survival analysis of patients with lung cancer prescribed APD

In univariate analysis, a significant difference in the OS rate was observed for patients with lung cancer treated with CCRT, depending on whether APD was prescribed. The 2-year OS rates for the APD (+) and APD (–) groups were 20.4% and 36.4%, respectively (p < 0.001) (Fig. 2). Male sex, age ≥ 80 years, higher CCI score, and accompanying hypertension, myocardial infarction, bipolar disorder, psychotic disorders, depression, and delirium were negative prognostic factors. Other psychiatric disorders were excluded from the analysis due to the diversity of conditions and ambiguity in their definitions. We performed multivariate analyses to determine the factors affecting OS. APD use during CCRT was a significant factor for worse OS (HR, 1.62; 95% CI, 1.55 to 1.69; p < 0.001). Moreover, male and age ≥ 80 years significantly affected OS (HR, 1.17 and 2.06, respectively; both p < 0.001). Underlying hypertension (HR, 1.11; 95% CI, 1.07 to 1.14; p < 0.001) and myocardial infarction (HR, 1.12; 95% CI, 1.05 to 1.21; p=0.002) were the significant factors for worse OS. Patients with a history of depression were also associated with poorer OS (HR, 1.10; 95% CI, 1.06 to 1.15; p < 0.001) (Table 3). In addition, we performed further survival analyses using the factors that were significant in the multivariate analyses. For men aged ≥ 80 years who took APDs during CCRT tended to result in worse OS compared with those who did not use APDs (p=0.094) (S1 Fig.). However, no statistically significant difference was observed in OS based on the number of comorbidities (hypertension, myocardial infarction, depression) in male patients with lung cancer aged ≥ 80 years who took APDs (p=0.989) (S2 Fig.).

A subgroup analysis was conducted in patients who took APDs during CCRT. This analysis incorporated APD prescription along with the variables evaluated for all patients who received CCRT. In univariate analysis, the pre-CCRT group exhibited a lower OS than the during-CCRT group, but no statistically significant difference was observed in multivariate analysis. Prescription dosage (low vs. high) and duration (within 6 months vs. over 6 months) showed no significant difference in OS (Table 4).

Discussion

Patients diagnosed with cancer frequently experience concurrent psychiatric disorders along with general psychological distress [16]. Among patients with cancer, 20%-40% experience significant levels of psychological issues, which can negatively impact their treatment course, quality of life, and even survival rates [17,18]. The patients with locally advanced lung cancer who receive CCRT are likely to experience more psychiatric disorders due to their greater tumor burden [2,6,18]. During the study period from 2010 to 2020, lung cancer treatment has advanced significantly, impacting OS rates based on the time of diagnosis. Concurrently, APD prescriptions have increased over time, reflecting the fact that more patients with lung cancer are experiencing psychological difficulties related to cancer treatment (Fig. 3). As shown in Fig. 3, a notable trend of decreasing mortality rates and increasing APD prescription rates was observed among patients with lung cancer. This demographic shift underscores the importance of investigating the psychological vulnerability of patients with lung cancer and the potential impact of APD use on their overall survival.

This study aimed to evaluate APD use in patients with lung cancer who received CCRT and assess its effect on survival. To our knowledge, this is the first study to report the prevalence of APD use and its effect during CCRT in patients with lung cancer in Korea.

Some studies have reported a lower cancer incidence rate within the schizophrenic population, which is likely due to APD use [19-21]. Jeong et al. [22] suggested that certain APDs, such as trifluoperazine, inhibit the progression of NSCLC based on anti-lung-cancer activity of trifluoperazine on A549 human lung cancer cells. In addition, Yang et al. [23] reported quetiapine as a radiosensitizer for liver cancer. Based on these biological grounds, we analyzed the effect of APDs use during CCRT on survival in patients with lung cancer. We hypothesized that the prescription of APDs during CCRT would positively impact survival in patients with locally advanced lung cancer. However, the use of APDs during CCRT was associated with poor prognosis in this study. In our study, a significant association was observed between APD use during CCRT and lower OS. Patients who took APDs had a significantly worse 2-year survival rate than those who did not. The primary APDs used during CCRT in our cohort were chlorpromazine and quetiapine. This finding likely reflects the fact that the study population comprised patients taking APDs during CCRT and is similar to results from a previous study examining APD use during radiotherapy across all cancer patients, including those with lung cancer [24].

Several factors may explain the observed association between APD use and reduced survival rates. First, patients prescribed APDs during CCRT exhibited higher rates of comorbidities including hypertension, myocardial infarction, and delirium, compared with those prescribed APDs over the entire period. These comorbid conditions can adversely affect the survival outcomes in patients with lung cancer. Individuals with such underlying health issues are more likely to be prescribed APDs, and the cumulative effects of these conditions may contribute to the observed decrease in survival rates. Furthermore, APD use may serve as an indicator of more advanced lung cancer or heightened psychological problems associated with the disease and its treatment. Patients with more aggressive cancer or those experiencing significant psychiatric issues may be more prone to receive APDs [25,26], and these factors independently influence survival rates. Second, the high mortality rate associated with psychiatric disorders may also account for the increased mortality among patients using APDs during CCRT. A meta-analysis indicated a pooled relative risk of all-cause mortality of 2.22 among individuals with mental disorders, including schizophrenia, depression, anxiety, and bipolar disorder [27]. In our study, we classified and analyzed psychiatric diagnoses to ascertain the reasons for APD use among patients who took APDs during CCRT. Although not all patients who took APDs had accompanying psychiatric diagnostic codes, those with psychiatric diagnoses demonstrated a statistically significant higher proportion among the patients who took APDs during CCRT. Third, APDs have various side effects, including sedation, metabolic disturbances, and cardiovascular complications [28,29]. These adverse effects can potentially exacerbate a patient’s overall health and treatment tolerance, leading to poorer clinical outcomes.

We also performed subgroup analysis of APD prescriptions that may affect survival in patients using APDs during CCRT. The pre-CCRT group exhibited a lower OS rate than did the during-CCRT group in univariate analysis, but this difference did not reach statistical significance in multivariable analysis. Prescription dosage and duration were also not significant prognostic factors. In patients who took APDs during CCRT, only a lower CCI score was a statistically significant good prognostic factor. These results suggest that the underlying status of patients forced to use APD rather than using APD itself likely contributed to the observed survival rates. Most of the APDs used during CCRT were prescribed during CCRT (80%) and was administered at a low dose (96.3%) and within 6 months (91.7%).

Understanding the rationale for the use of APDs in real-world settings is crucial, as valid reasons for their prescription that suggest the therapeutic benefits may outweigh potential side effects. APDs are frequently prescribed in patients with cancer for various reasons. They are commonly used as adjunctive therapy or monotherapy for managing psychotic symptoms, such as delusions and hallucinations, as well as manic symptoms. Atypical APDs may also serve as adjunctive or monotherapy for managing depressive symptoms that show a weak response to traditional antidepressants, often at higher doses covered by medical insurance. Furthermore, APDs are indicated as adjunctive treatment when psychological distress—such as depression, anxiety, and insomnia—fails to improve with standard antidepressants or anxiolytics. They may also be used to manage delirium and alleviate chemotherapy- or radiotherapy-induced nausea and vomiting, often in off-label and lower doses. Our findings suggest that delirium during CCRT likely contributes to the need for a regimen involving low-dose APDs for short durations. In our study, the proportion of patients with delirium diagnostic codes was extremely low, but in reality, the number of patients experiencing delirium is likely much higher. This is presumably attributed to the fact that delirium among patients with cancer may often be coded under other psychiatric diagnostic codes or not specified in clinical practice. APDs are used for the pharmacological management of delirium and should be administered at the lowest appropriate dose [29]. It is possible that the reason for starting APD during CCRT and using APD for less than 6 months was due to the clinical course of delirium. Additionally, the most commonly used APD in our study was quetiapine, which is often the primary choice for older patients with delirium due to its low incidence of extrapyramidal side effects [30]. Delirium is the most common neurological condition in patients with cancer and is more commonly observed in older patients. Studies have shown that 22%-44% of patients with cancer experience delirium, and the incidence rises to 87% in the final days of life [31]. Although we cannot be completely sure if most patients who took APD during CCRT in our study had delirium, this could be one of the reasons for the high mortality rate. In admitted patients with terminal cancer, higher mortality rates have been reported in patients with delirium than in those without it [32]. Further studies on the effects of APDs on cancer treatment and prognosis are needed.

This study has limitations inherent to its observational design. In an actual clinical setting, APD prescriptions in hospitalized patients during CCRT are often made without coding for delirium (F05 code). In addition, the possibility of APDs prescribed under incorrect F codes cannot be ignored. Our study established an association between APD and OS, but we did not definitively prove that APD use directly resulted in lower survival rates in patients with lung cancer treated with CCRT. This study was based on medical claims, not medical chart reviews. Given the limited clinical presentations in the NHIS dataset, non-claims information, such as smoking or other factors affecting survival, was excluded from the analyses. Additionally, not all the claimed comorbidities were used in the analyses of the factors affecting OS due to the wide variety of underlying conditions. Hence, caution should be taken in interpreting our findings, especially considering that certain non-claim data were not reflected. In particular, the lack of information on staging may limit the clinical application of the findings. However, we predicted locally advanced stages in a relatively limited cohort of patients with lung cancer who had received CCRT. We also focused on comorbidities, such as cardiovascular disease or psychiatric disorders, which may be associated with chest irradiation or APD prescription. Particularly, quetiapine, the most commonly prescribed drug, may increase the risk of major cardiovascular events, and RT to the lung can cause cardiac toxicity [33-35]. Nevertheless, as mentioned above, the inability to accurately identify clinical cases using APD is an inevitable limitation of this study using NHIS data. Nonetheless, this study reflects actual clinical situations related to APD use, and we believe that additional research using electronic medical record that can yield detailed information based on individual data is needed.

Taken together, this is the first study to report on the use of APDs in the growing population of older patients with lung cancer in real-world practice in Korea. We found that 11.5% of the patients with lung cancer took APDs during CCRT. The study’s results highlight the potential negative association between APD use during CCRT and survival in patients with lung cancer. The high mortality rate observed in patients with lung cancer who took APDs during CCRT could be influenced by the underlying conditions that necessitated APD use. Further studies are needed to determine the effects of APD use during CCRT in patients with lung cancer.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2024-554_S1_Fig.pdf

crt-2024-554_S2_Fig.pdf

NOTES

Ethical Statement

This study was approved by the Institutional Review Board of Chung-Ang University Hospital (IRB No. 2202-022-19407). The data was provided with an anonymous identification code, which makes it impossible for the researchers to identify any patient. Therefore, the need for informed consent was waived.

Author Contributions

Conceived and designed the analysis: Kim DY, Hwang IG, Kim SM, Park SY, Lee H, Choi JH.

Collected the data: Kim DY, Hwang IG, Kim SM, Choi JH.

Contributed data or analysis tools: Kim DY, Hwang IG, Kim SM, Kang DR, Go TH, Hong SH, Choi JH.

Performed the analysis: Kim DY, Kang DR, Go TH, Hong SH, Choi JH.

Wrote the paper: Kim DY, Choi JH.

Conflict of Interest

Financial support for this study was obtained from VSPharm Tech Co., Ltd., South Korea.

Fig. 1.

Flowchart of patient selection. NHIS, National Health Insurance Service.

Fig. 2.

Overall survival curves of patients with lung cancer treated with concurrent chemoradiotherapy according to the prescription of antipsychotic drugs (APDs).

Fig. 3.

Mortality rates and antipsychotic drugs (APDs) prescription rates between 2010 and 2020.

Table 1.

Baseline characteristics of patients with lung cancer who received CCRT according to the prescriptions of antipsychotic drugs

Category	CCRT (n=23,099)		p-value
Category	APD (–) (n=20,437)	APD (+) (n=2,662)	p-value
Sex
Male	16,553 (81.0)	2,375 (89.2)	< 0.001
Female	3,884 (19.0)	287 (10.8)
Age (yr)	63.45±9.34	65.24±8.99	< 0.001 (continuous)
< 30s	33 (0.2)	1 (0.1)	< 0.001 (categorical)
30s	233 (1.1)	18 (0.7)
40s	1,261 (6.2)	115 (4.3)
50s	4,867 (23.8)	542 (20.4)
60s	8,425 (41.2)	1,071 (40.2)
70s	5,122 (25.1)	821 (30.8)
≥ 80s	496 (2.4)	94 (3.5)
CCI	3.75±2.85	3.91±2.94	< 0.001 (continuous)
0	1,056 (5.1)	125 (4.7)	< 0.001 (categorical)
1	3,343 (16.4)	425 (16.0)
2	4,473 (21.9)	543 (20.4)
≥ 3	11,565 (56.6)	1,569 (58.9)
Medical history
Hypertension (I10-I15)	10,690 (52.3)	1,619 (60.8)	< 0.001
Myocardial infarction (I21, I22)	923 (4.5)	174 (6.5)	< 0.001
Psychiatric history
Bipolar disorder (F30, F31)	334 (1.6)	271 (10.2)	< 0.001
Psychotic disorder (F20-F29)	183 (0.9)	118 (4.4)	< 0.001
Depressive disorder (F32-F34)	3,913 (19.2)	801 (30.1)	< 0.001
Delirium (F05)	106 (0.5)	57 (2.1)	< 0.001
Other psychiatric disorders (F00-F99)	3,273 (16.0)	603 (22.7)	< 0.001

Values are presented as number (%) or mean±SD. APD, antipsychotic drugs; CCI, Charlson Comorbidity Index; CCRT, concurrent chemoradiotherapy; SD, standard deviation.

Table 2.

Type and details of the antipsychotic drugs prescribed to the patients during CCRT

Antipsychotic prescription	No. (%) (n=2,662)
Antipsychotic prescription (duplicate allowed)	2,807
Aripiprazole	0
Chlorpromazine	1,028 (36.6)
Haloperidol	0
Olanzapine	250 (8.9)
Quetiapine	1,327 (47.3)
Risperidone	202 (7.2)
Simple prescription	2,521
Chlorpromazine	985 (39.1)
Haloperidol	0
Olanzapine	207 (8.2)
Quetiapine	1,199 (47.6)
Risperidone	130 (5.2)
Complex prescription	141
2	137 (97.2)
≥ 3	4 (2.8)
Prescription time
Pre-CCRT	533 (20.0)
During-CCRT	2,129 (80.0)
Prescription dosage^a)
Low dose	2,428 (96.3)
High dose	93 (3.7)
Prescription duration^a)
Within 6 months	2,313 (91.7)
Over 6 months	208 (8.3)

Prescription details included timing, dosage (low vs. high), and duration. CCRT, concurrent chemoradiotherapy.

^a) The information of prescription dose and duration were available for only 2,521 patients.

Table 3.

Univariate and multivariate analyses of prognostic factors for overall survival in patients with lung cancer who received CCRT

Variable	Univariate analysis		Multivariate analysis
Variable	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex
Male (vs. female)	1.23 (1.19-1.28)	< 0.001	1.17 (1.12-1.21)	< 0.001
Age (yr)
< 30s	Reference		Reference
30-59	1.07 (0.72-1.6)	0.728	1.03 (0.69-1.54)	0.874
60-79	1.36 (0.91-2.02)	0.136	1.29 (0.87-1.93)	0.208
≥ 80s	2.18 (1.45-3.28)	< 0.001	2.06 (1.37-3.11)	< 0.001
Hypertension
Yes (vs. no)	1.15 (1.12-1.19)	< 0.001	1.11 (1.07-1.14)	< 0.001
Myocardial infarction
Yes (vs. no)	1.18 (1.10-1.27)	< 0.001	1.12 (1.05-1.21)	0.002
Bipolar disorder
Yes (vs. no)	1.32 (1.21-1.45)	< 0.001	1.05 (0.95-1.16)	0.345
Psychotic disorders
Yes (vs. no)	1.27 (1.12-1.45)	< 0.001	1.05 (0.92-1.2)	0.459
Depression
Yes (vs. no)	1.13 (1.09-1.17)	< 0.001	1.10 (1.06-1.15)	< 0.001
Delirium
Yes (vs. no)	1.42 (1.19-1.69)	< 0.001	1.16 (0.97-1.38)	0.102
CCI
0-2 (vs. ≥ 3)	0.75 (0.73-0.78)	< 0.001	0.70 (0.68-0.72)	< 0.001
APD
APD (vs. without APD)	1.70 (1.62-1.78)	< 0.001	1.62 (1.55-1.69)	< 0.001

APD, antipsychotic drugs; CCI, Charlson Comorbidity Index; CCRT, concurrent chemoradiotherapy; CI, confidence interval; HR, hazard ratio.

Table 4.

Univariate and multivariate analyses of prognostic factors for overall survival in patients who took APDs during CCRT

Variable	Univariate analysis		Multivariate analysis
Variable	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex
Male (vs. female)	0.96 (0.84-1.10)	0.566	0.95 (0.82-1.09)	0.439
Age (yr)
< 30s	Reference		Reference
30-59	0.33 (0.05-2.36)	0.272	0.38 (0.05-2.68)	0.330
60-79	0.43 (0.06-3.05)	0.399	0.49 (0.07-3.48)	0.476
≥ 80s	0.70 (0.10-4.98)	0.719	0.81 (0.11-5.82)	0.835
Hypertension
Yes (vs. no)	1.12 (0.02-1.12)	0.015	1.10 (1.01-1.21)	0.038
Myocardial infarction
Yes (vs. no)	1.00 (0.84-1.18)	0.958	1.00 (0.83-1.19)	0.962
Bipolar disorder
Yes (vs. no)	1.03 (0.89-1.19)	0.704	1.04 (0.87-1.25)	0.682
Psychotic disorders
Yes (vs. no)	0.98 (0.78-1.12)	0.826	1.04 (0.80-1.34)	0.786
Depression
Yes (vs. no)	1.01 (0.92-1.10)	0.916	1.03 (0.93-1.14)	0.563
Delirium
Yes (vs. no)	1.31 (0.98-1.76)	0.072	1.35 (1.00-1.83)	0.052
CCI
0-2 (vs. ≥ 3)	0.74 (0.68-0.81)	< 0.001	0.70 (0.64-0.77)	< 0.001
APD prescription time
Pre-CCRT (vs. during-CCRT)	1.75 (1.25-2.06)	< 0.001	0.95 (0.82-1.10)	0.499
APD prescription dosage
Low (vs. high)	0.96 (0.76-1.20)	0.692	0.97 (0.78-1.23)	0.825
APD prescription duration
≤ 6 mo (vs. > 6 mo)	1.06 (0.90-1.24)	0.498	1.03 (0.83-1.27)	0.791

APD, antipsychotic drugs; CCI, Charlson Comorbidity Index; CCRT, concurrent chemoradiotherapy; CI, confidence interval; HR, hazard ratio.

REFERENCES

1. Prapa P, Papathanasiou IV, Bakalis V, Malli F, Papagiannis D, Fradelos EC. Quality of life and psychological distress of lung cancer patients undergoing chemotherapy. World J Oncol. 2021;12:61–6. Article PubMed PMC
2. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023;20:624–39. Article PubMed PDF
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. Article PubMed PDF
4. Kim R, Keam B, Hahn S, Ock CY, Kim M, Kim TM, et al. First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: a systematic review and network meta-analysis. Clin Lung Cancer. 2019;20:331–8. Article PubMed
5. Lee JG, Kim HC, Choi CM. Recent trends of lung cancer in Korea. Tuberc Respir Dis (Seoul). 2021;84:89–95. Article PubMed PMC PDF
6. Kim HC, Jung CY, Cho DG, Jeon JH, Lee JE, Ahn JS, et al. Clinical characteristics and prognostic factors of lung cancer in Korea: a pilot study of data from the Korean Nationwide Lung Cancer Registry. Tuberc Respir Dis (Seoul). 2019;82:118–25. Article PubMed PMC PDF
7. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer. 2007;110:1665–76. Article PubMed
8. Akechi T, Nakano T, Okamura H, Ueda S, Akizuki N, Nakanishi T, et al. Psychiatric disorders in cancer patients: descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. Jpn J Clin Oncol. 2001;31:188–94. Article PubMed
9. Ng CG, Boks MP, Smeets HM, Zainal NZ, de Wit NJ. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22:762–7. Article PubMed
10. Fisch MJ, Kim HF. Use of atypical antipsychotic agents for symptom control in patients with advanced cancer. J Support Oncol. 2004;2:447–52. PubMed
11. Thekdi SM, Trinidad A, Roth A. Psychopharmacology in cancer. Curr Psychiatry Rep. 2015;17:529.Article PubMed PDF
12. Weinberger MI, Bruce ML, Roth AJ, Breitbart W, Nelson CJ. Depression and barriers to mental health care in older cancer patients. Int J Geriatr Psychiatry. 2011;26:21–6. Article PubMed PMC
13. Liperoti R, Fusco D, Cipriani MC, Lo Monaco MR, Onder G. Balancing the risks and benefits of antipsychotic medications for symptom management in older patients with cancer. J Geriatr Oncol. 2018;9:693–5. Article PubMed
14. Muzyka M, Tagliafico L, Serafini G, Baiardini I, Braido F, Nencioni A, et al. Neuropsychiatric disorders and frailty in older adults over the spectrum of cancer: a narrative review. Cancers (Basel). 2022;14:258.Article PubMed PMC
15. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull. 2014;40:314–26. Article PubMed PMC
16. Holland JC, Alici Y. Management of distress in cancer patients. J Support Oncol. 2010;8:4–12. PubMed
17. Ostovar S, Modarresi Chahardehi A, Mohd Hashim IH, Othman A, Kruk J, Griffiths MD. Prevalence of psychological distress among cancer patients in Southeast Asian countries: a systematic review. Eur J Cancer Care (Engl). 2022;31:e13669Article PubMed PMC PDF
18. Sullivan DR, Forsberg CW, Ganzini L, Au DH, Gould MK, Provenzale D, et al. Longitudinal changes in depression symptoms and survival among patients with lung cancer: a national cohort assessment. J Clin Oncol. 2016;34:3984–91. Article PubMed PMC
19. Lin CY, Lane HY, Chen TT, Wu YH, Wu CY, Wu VY. Inverse association between cancer risks and age in schizophrenic patients: a 12-year nationwide cohort study. Cancer Sci. 2013;104:383–90. Article PubMed PMC
20. Ji J, Sundquist K, Ning Y, Kendler KS, Sundquist J, Chen X. Incidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in Sweden. Schizophr Bull. 2013;39:527–36. Article PubMed PMC
21. Osborn DP, Limburg H, Walters K, Petersen I, King M, Green J, et al. Relative incidence of common cancers in people with severe mental illness: cohort study in the United Kingdom THIN primary care database. Schizophr Res. 2013;143:44–9. Article PubMed
22. Jeong JY, Park H, Yoo H, Kim EJ, Jeon B, Lee JD, et al. Trifluoperazine and its analog suppressed the tumorigenicity of non-small cell lung cancer cell: applicability of antipsychotic drugs to lung cancer treatment. Biomedicines. 2022;10:1046.Article PubMed PMC
23. Yang JD, Liu YC, Wang HC, Hsu FT, Liao TL, Huang MC, et al. Quetiapine significantly improves the effectiveness of radiotherapy in combating hepatocellular carcinoma progression in a Hep3B xenograft mouse model. In Vivo. 2024;38:1079–93. Article PubMed PMC
24. Hwang IG, Park SE, Kim SM, Kang DR, Go TH, Hong SH, et al. Use of antipsychotic drugs during radiotherapy in adult cancer patients in Korea: a nationwide retrospective cohort study based on the national health insurance service database. Radiat Oncol. 2024;19:171.Article PubMed PMC PDF
25. Alici Y, Weiss T, Holland JC, Nelson C, Roth A. Common psychiatric problems in older patients with cancer: report of one-year experience of a psychiatry outpatient clinic. J Geriatr Oncol. 2011;2:137–41. Article
26. Lu D, Andersson TM, Fall K, Hultman CM, Czene K, Valdimarsdottir U, et al. Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in Sweden. JAMA Oncol. 2016;2:1188–96. Article PubMed
27. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334–41. Article PubMed PMC
28. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with anti-psychotic drugs. Nat Rev Endocrinol. 2011;8:114–26. Article PubMed PDF
29. Harbell MW, Dumitrascu C, Bettini L, Yu S, Thiele CM, Koyyalamudi V. Anesthetic considerations for patients on psychotropic drug therapies. Neurol Int. 2021;13:640–58. Article PubMed PMC
30. Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont). 2008;5:29–36.
31. Teles AL, Baldacara L, Silva AG, Leite VD, Benito AL, Ribeiro FV. Interfaces between oncology and psychiatry. Rev Assoc Med Bras (1992). 2024;70:e2024S129Article PubMed PMC
32. Fang CK, Chen HW, Liu SI, Lin CJ, Tsai LY, Lai YL. Prevalence, detection and treatment of delirium in terminal cancer inpatients: a prospective survey. Jpn J Clin Oncol. 2008;38:56–63. Article PubMed
33. Hojlund M, Andersen K, Ernst MT, Correll CU, Hallas J. Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry. 2022;21:444–51. Article PubMed PMC PDF
34. Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol. 2010;21:1825–33. Article PubMed PMC
35. Banfill K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol. 2021;16:216–27. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study

Cancer Res Treat. 2025;57(4):1030-1039. Published online February 6, 2025

DOI: https://doi.org/10.4143/crt.2024.554

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study

Fig. 1. Flowchart of patient selection. NHIS, National Health Insurance Service.

Fig. 2. Overall survival curves of patients with lung cancer treated with concurrent chemoradiotherapy according to the prescription of antipsychotic drugs (APDs).

Fig. 3. Mortality rates and antipsychotic drugs (APDs) prescription rates between 2010 and 2020.

Fig. 1.

Fig. 2.

Fig. 3.

Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study

Category	CCRT (n=23,099)		p-value
Category	APD (–) (n=20,437)	APD (+) (n=2,662)	p-value
Sex
Male	16,553 (81.0)	2,375 (89.2)	< 0.001
Female	3,884 (19.0)	287 (10.8)
Age (yr)	63.45±9.34	65.24±8.99	< 0.001 (continuous)
< 30s	33 (0.2)	1 (0.1)	< 0.001 (categorical)
30s	233 (1.1)	18 (0.7)
40s	1,261 (6.2)	115 (4.3)
50s	4,867 (23.8)	542 (20.4)
60s	8,425 (41.2)	1,071 (40.2)
70s	5,122 (25.1)	821 (30.8)
≥ 80s	496 (2.4)	94 (3.5)
CCI	3.75±2.85	3.91±2.94	< 0.001 (continuous)
0	1,056 (5.1)	125 (4.7)	< 0.001 (categorical)
1	3,343 (16.4)	425 (16.0)
2	4,473 (21.9)	543 (20.4)
≥ 3	11,565 (56.6)	1,569 (58.9)
Medical history
Hypertension (I10-I15)	10,690 (52.3)	1,619 (60.8)	< 0.001
Myocardial infarction (I21, I22)	923 (4.5)	174 (6.5)	< 0.001
Psychiatric history
Bipolar disorder (F30, F31)	334 (1.6)	271 (10.2)	< 0.001
Psychotic disorder (F20-F29)	183 (0.9)	118 (4.4)	< 0.001
Depressive disorder (F32-F34)	3,913 (19.2)	801 (30.1)	< 0.001
Delirium (F05)	106 (0.5)	57 (2.1)	< 0.001
Other psychiatric disorders (F00-F99)	3,273 (16.0)	603 (22.7)	< 0.001

Antipsychotic prescription	No. (%) (n=2,662)
Antipsychotic prescription (duplicate allowed)	2,807
Aripiprazole	0
Chlorpromazine	1,028 (36.6)
Haloperidol	0
Olanzapine	250 (8.9)
Quetiapine	1,327 (47.3)
Risperidone	202 (7.2)
Simple prescription	2,521
Chlorpromazine	985 (39.1)
Haloperidol	0
Olanzapine	207 (8.2)
Quetiapine	1,199 (47.6)
Risperidone	130 (5.2)
Complex prescription	141
2	137 (97.2)
≥ 3	4 (2.8)
Prescription time
Pre-CCRT	533 (20.0)
During-CCRT	2,129 (80.0)
Prescription dosage^a)
Low dose	2,428 (96.3)
High dose	93 (3.7)
Prescription duration^a)
Within 6 months	2,313 (91.7)
Over 6 months	208 (8.3)

Variable	Univariate analysis		Multivariate analysis
Variable	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex
Male (vs. female)	1.23 (1.19-1.28)	< 0.001	1.17 (1.12-1.21)	< 0.001
Age (yr)
< 30s	Reference		Reference
30-59	1.07 (0.72-1.6)	0.728	1.03 (0.69-1.54)	0.874
60-79	1.36 (0.91-2.02)	0.136	1.29 (0.87-1.93)	0.208
≥ 80s	2.18 (1.45-3.28)	< 0.001	2.06 (1.37-3.11)	< 0.001
Hypertension
Yes (vs. no)	1.15 (1.12-1.19)	< 0.001	1.11 (1.07-1.14)	< 0.001
Myocardial infarction
Yes (vs. no)	1.18 (1.10-1.27)	< 0.001	1.12 (1.05-1.21)	0.002
Bipolar disorder
Yes (vs. no)	1.32 (1.21-1.45)	< 0.001	1.05 (0.95-1.16)	0.345
Psychotic disorders
Yes (vs. no)	1.27 (1.12-1.45)	< 0.001	1.05 (0.92-1.2)	0.459
Depression
Yes (vs. no)	1.13 (1.09-1.17)	< 0.001	1.10 (1.06-1.15)	< 0.001
Delirium
Yes (vs. no)	1.42 (1.19-1.69)	< 0.001	1.16 (0.97-1.38)	0.102
CCI
0-2 (vs. ≥ 3)	0.75 (0.73-0.78)	< 0.001	0.70 (0.68-0.72)	< 0.001
APD
APD (vs. without APD)	1.70 (1.62-1.78)	< 0.001	1.62 (1.55-1.69)	< 0.001

Variable	Univariate analysis		Multivariate analysis
Variable	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex
Male (vs. female)	0.96 (0.84-1.10)	0.566	0.95 (0.82-1.09)	0.439
Age (yr)
< 30s	Reference		Reference
30-59	0.33 (0.05-2.36)	0.272	0.38 (0.05-2.68)	0.330
60-79	0.43 (0.06-3.05)	0.399	0.49 (0.07-3.48)	0.476
≥ 80s	0.70 (0.10-4.98)	0.719	0.81 (0.11-5.82)	0.835
Hypertension
Yes (vs. no)	1.12 (0.02-1.12)	0.015	1.10 (1.01-1.21)	0.038
Myocardial infarction
Yes (vs. no)	1.00 (0.84-1.18)	0.958	1.00 (0.83-1.19)	0.962
Bipolar disorder
Yes (vs. no)	1.03 (0.89-1.19)	0.704	1.04 (0.87-1.25)	0.682
Psychotic disorders
Yes (vs. no)	0.98 (0.78-1.12)	0.826	1.04 (0.80-1.34)	0.786
Depression
Yes (vs. no)	1.01 (0.92-1.10)	0.916	1.03 (0.93-1.14)	0.563
Delirium
Yes (vs. no)	1.31 (0.98-1.76)	0.072	1.35 (1.00-1.83)	0.052
CCI
0-2 (vs. ≥ 3)	0.74 (0.68-0.81)	< 0.001	0.70 (0.64-0.77)	< 0.001
APD prescription time
Pre-CCRT (vs. during-CCRT)	1.75 (1.25-2.06)	< 0.001	0.95 (0.82-1.10)	0.499
APD prescription dosage
Low (vs. high)	0.96 (0.76-1.20)	0.692	0.97 (0.78-1.23)	0.825
APD prescription duration
≤ 6 mo (vs. > 6 mo)	1.06 (0.90-1.24)	0.498	1.03 (0.83-1.27)	0.791

Table 1. Baseline characteristics of patients with lung cancer who received CCRT according to the prescriptions of antipsychotic drugs

Values are presented as number (%) or mean±SD. APD, antipsychotic drugs; CCI, Charlson Comorbidity Index; CCRT, concurrent chemoradiotherapy; SD, standard deviation.

Table 2. Type and details of the antipsychotic drugs prescribed to the patients during CCRT

Prescription details included timing, dosage (low vs. high), and duration. CCRT, concurrent chemoradiotherapy.

The information of prescription dose and duration were available for only 2,521 patients.

Table 3. Univariate and multivariate analyses of prognostic factors for overall survival in patients with lung cancer who received CCRT

APD, antipsychotic drugs; CCI, Charlson Comorbidity Index; CCRT, concurrent chemoradiotherapy; CI, confidence interval; HR, hazard ratio.

Table 4. Univariate and multivariate analyses of prognostic factors for overall survival in patients who took APDs during CCRT

APD, antipsychotic drugs; CCI, Charlson Comorbidity Index; CCRT, concurrent chemoradiotherapy; CI, confidence interval; HR, hazard ratio.